Terminated PHASE3 INTERVENTIONAL 1-arm NCT03080935

Fourier Open-label Extension Study in Subjects With Clinically Evident Cardiovascular Disease in Selected European Countries

A Multicenter, Open-label, Single-arm, Extension Study to Assess Long-term Safety of Evolocumab Therapy in Subjects With Clinically Evident Cardiovascular Disease in Selected European Countries

Sponsor: Amgen

Conditions Dyslipidemia

Interventions Evolocumab

Updated 21 times since 2017 Last updated: May 10, 2024 Started: Mar 13, 2017 Primary completion: Mar 4, 2022 Completion: Mar 4, 2022

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Amgen business decision to close study early

Other terminated trials from Amgen

See all terminations from Amgen

A PHASE3 clinical study on Dyslipidemia, this trial is terminated or withdrawn. The trial is conducted by Amgen and has accumulated 21 data snapshots since 2017. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

21 versions recorded

Sep 2025 — Present [monthly]

Terminated PHASE3
Sep 2024 — Sep 2025 [monthly]

Terminated PHASE3
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE3
Jun 2024 — Jul 2024 [monthly]

Terminated PHASE3
Apr 2023 — Jun 2024 [monthly]

Terminated PHASE3

▶ Show 16 earlier versions

Feb 2023 — Apr 2023 [monthly]

Terminated PHASE3

Status: Completed → Terminated
Apr 2022 — Feb 2023 [monthly]

Completed PHASE3

Status: Active Not Recruiting → Completed
Jan 2022 — Apr 2022 [monthly]

Active Not Recruiting PHASE3
Oct 2021 — Jan 2022 [monthly]

Active Not Recruiting PHASE3
Jan 2021 — Oct 2021 [monthly]

Active Not Recruiting PHASE3
Dec 2020 — Jan 2021 [monthly]

Active Not Recruiting PHASE3
Dec 2019 — Dec 2020 [monthly]

Active Not Recruiting PHASE3
Jun 2019 — Dec 2019 [monthly]

Active Not Recruiting PHASE3
Nov 2018 — Jun 2019 [monthly]

Active Not Recruiting PHASE3
Jun 2018 — Nov 2018 [monthly]

Active Not Recruiting PHASE3
Dec 2017 — Jun 2018 [monthly]

Active Not Recruiting PHASE3

Status: Recruiting → Active Not Recruiting
Aug 2017 — Dec 2017 [monthly]

Recruiting PHASE3
Jul 2017 — Aug 2017 [monthly]

Recruiting PHASE3
Jun 2017 — Jul 2017 [monthly]

Recruiting PHASE3
May 2017 — Jun 2017 [monthly]

Recruiting PHASE3
Apr 2017 — May 2017 [monthly]

Recruiting PHASE3

First recorded

Mar 2017

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Amgen

Data source: Amgen

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Aalborg, Denmark , Aalst, Belgium , Aarhus N, Denmark , Almada, Portugal , Antwerp, Belgium , Bad Krozingen, Germany , Ballerup Municipality, Denmark , Bergamo, Italy , Berlin, Germany , Besançon, France and 59 more locations